Cue Biopharma Stock News

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modula

Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d

During the last session, Cue Biopharma Inc. (NASDAQ:CUE)’s traded shares were 0.48 million, with the beta value of the company hitting 1.64. At the end of the trading day, the stock’s price was $4.76, reflecting an intraday loss of -4.03% or -$0.2. The 52-week high for the CUE share is $18.42, that puts it down … Can Cue Biopharma Inc. (NASDAQ: CUE) Still Be Considered A Loss When It’s Down -57.91% YTD? Read More »

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will present at the Oppenheimer 32nd Annual Healthcare Conference being held virtually March 15-17.

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea

Aridis Pharmaceuticals ARDS +27%. Galapagos GLPG +16%. Immix Biopharma IMMX +15%. Epizyme (EPZM) -34%. Cue Biopharma (CUE) -16%.

Cue Biopharma, Inc. (CUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv

Wall Street brokerages expect Cue Biopharma, Inc. (NASDAQ:CUE) to post $6.50 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Cue Biopharmas earnings, with the highest sales estimate coming in at $10.85 million and the lowest estimate coming in at $2.16 million. Cue Biopharma reported sales of $480,000.00 [] The post Analysts Expect Cue Biopharma, Inc. (NASDAQ:CUE) Will Post Quarterly Sales of $6.50 Million appeared first on ETF Daily News .

CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today the appointment of Patricia Nasshorn, as Chief Business Officer, effective December 15th, 2021.

Equities analysts predict that Cue Biopharma, Inc. (NASDAQ:CUE) will report earnings per share of ($0.30) for the current quarter, according to Zacks. Two analysts have made estimates for Cue Biopharmas earnings. The highest EPS estimate is ($0.20) and the lowest is ($0.40). Cue Biopharma posted earnings of ($0.37) per share during the same quarter last []

Wall Street brokerages expect Cue Biopharma, Inc. (NASDAQ:CUE) to post $6.50 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Cue Biopharma’s earnings, with the highest sales estimate coming in at $10.85 million and the lowest estimate coming in at $2.16 million. Cue Biopharma reported […]

CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patients body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held on November 29-December 2, 2021.